Amendment #1 to Option Purchase Agreement CD38-GEAR-NK(Auto)Option Purchase Agreement • August 19th, 2021 • Coeptis Therapeutics Inc. • Pharmaceutical preparations
This Amendment #1 (the “Amendment #1”) to the CD38-GEAR-NK(Auto) Option Purchase Agreement dated April 26, 2021 (the “Agreement”) is made and entered into by and between VyGen-Bio, Inc., (“VyGen-Bio”) and Coeptis Pharmaceuticals, Inc. (“Coeptis”) and for good and valuable consideration.
